The authors assessed the efficacy of trauma memory reactivation performed under the influence of propranolol, a noradrenergic beta-receptor blocker, as a putative reconsolidation blocker, in reducing symptoms of posttraumatic stress disorder (PTSD).

This was a 6-week, double-blind, placebo-controlled, randomized clinical trial in 60 adults diagnosed with long-standing PTSD. Propranolol or placebo was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks. The hypothesis predicted a significant treatment effect of trauma reactivation with propranolol compared with trauma reactivation with placebo in reducing PTSD symptoms on both the Clinician-Administered PTSD Scale (CAPS) and the patient-rated PTSD Checklist–Specific (PCL-S) in an intention-to-treat analysis.

The estimated group difference in posttreatment CAPS score, adjusted for pretreatment values (analysis of covariance), was a statistically significant 11.50. The within-group pre- to posttreatment effect sizes (Cohen’s d) were 1.76 for propranolol and 1.25 for placebo. For the PCL-S, the mixed linear model’s estimated time-by-group interaction yielded an average decrease of 2.43 points per week, for a total significant difference of 14.58 points above that of placebo. The pre- to posttreatment effect sizes were 2.74 for propranolol and 0.55 for placebo. Per protocol analyses for both outcomes yielded similar significant results.

Pre-reactivation propranolol, a treatment protocol suggested by reconsolidation theory, appears to be a novel and efficacious treatment for PTSD. Replication studies using a long-term follow-up in various trauma populations are required.

作者评估了在普萘洛尔（一种去甲肾上腺素β受体阻滞剂）作为推定的巩固阻滞剂的影响下减轻创伤后应激障碍（PTSD）症状而进行的创伤记忆恢复的功效。

这是一项为期6周，双盲，安慰剂对照，随机的临床试验，涉及60位被诊断患有长期PTSD的成年人。在短暂记忆恢复之前的90分钟内服用普萘洛尔或安慰剂，每周一次，连续6周。假说预测，在临床医师管理的PTSD量表（CAPS）和患者评估的PTSD清单特定（PCL-S）上，普萘洛尔与安慰剂对创伤再激活相比，在减轻PTSD症状方面具有显着的治疗效果。到治疗分析。

经校正治疗前值（协方差分析）后，估计的治疗后CAPS评分的组间差异为统计学上显着的11.50。普萘洛尔治疗前后的效应大小（Cohen d）为1.76，安慰剂为1.25。对于PCL-S，混合线性模型估计的按组交互时间每周平均减少2.43点，与安慰剂相比，总的显着差异为14.58点。普萘洛尔治疗前后的效果大小为2.74，安慰剂为0.55。根据方案分析，两种结果均产生相似的显着结果。

预激活普萘洛尔，一种由巩固理论提出的治疗方案，似乎是对PTSD的一种新颖有效的治疗方法。需要在各种创伤人群中进行长期随访的复制研究。